StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
038460.KQ$3045.00-2.56%
Fair $3045.00+0.0%

038460.KQ

BioSmart Co.,Ltd.

Unknown / UnknownKOSDAQ

$3045.00

-80.00 (-2.56%)

Fairly Valued+0.0%Fair Value $3045.00Fund rank 25/100 · Data gapFallback financials|
SA 44/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $-5.0B · quality 49.0/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 18/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

44/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 038460.KQLocal privado en este navegador · BioSmart Co.,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$77.0B

P/E

8.6x

↓

EV/EBITDA

4.9x

↓

ROE

6.3%

↑

Gross Margin

17.7%

↓

Debt/Equity

0.53

↑
52-Week Range$3045
$2630$6930

TradingView lightweight chart

038460.KQ price, volumen y niveles de valoración

Último $3,045Periodo -93.3%
Fair value: $3,045

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+7.2%

FCF CAGR

—

FCF margin

-2.0%

FCF / Net income

-1.08x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $482.78B · net income $9.01B · FCF $-9.69B

2022-FY → 2025-FY

Gross margin

17.7%-1.9% pts

Operating margin

4.7%+2.9% pts

Net margin

1.9%+1.7% pts

FCF margin

-2.0%-2.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$482.78B$482.78B$484.31B$456.16B$391.82B
Net Income$9.01B$9.01B$127.2M$17.91B$721.3M
EBITDA$25.02B$25.02B$19.90B$35.63B$15.92B
EPS356.00356.006.00557.0038.00
Gross Margin17.7%17.7%17.0%17.3%19.6%
Operating Margin4.7%4.7%4.2%2.2%1.8%
Net Margin1.9%1.9%0.0%3.9%0.2%
Balance Sheet
Debt/Equity0.530.530.410.700.86
Cash Flow
Free Cash Flow$-9.69B$-9.69B$-4.95B$-3.75B$421.8M
Returns
ROE6.3%6.3%0.1%16.0%0.7%
Valuation
P/E8.558.55547.506.1592.37
EV/EBITDA4.914.915.634.698.20
P/B0.540.540.540.990.69
Growth & Yield
Revenue Growth-0.3%-0.3%6.2%16.4%—
EPS Growth5833.3%5833.3%-98.9%1365.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-8.8%

fácil

EPS terminal req.

$270.19

Spread vs growth

5842.1%

5Y implied EPS CAGR

-1.7%

fácil

EPS terminal req.

$326.93

Spread vs growth

5835.0%

10Y implied EPS CAGR

4.0%

fácil

EPS terminal req.

$526.53

Spread vs growth

5829.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -14.6%

Total return

-14.6%

Start / end P/E

594.2x → 8.6x

EPS bridge

6.00 → 356.00

Residual

-5749.4%

EPS growth+5833.3%
Multiple rerating-98.6%
Dividend+0.0%
Residual / FX / buybacks / cross-term-5749.4%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.